|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02329 GLORY HEALTH
Nominal 
0.133 +0.010 (+8.130%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 2,506,285 | -35.813% | 3,904,672 | 9,898,401 | 5,768,896 | 8,093,176 |
| Cost of Sales | (2,556,565) | -32.565% | (3,791,155) | (8,651,166) | (4,788,575) | (5,954,455) |
| Gross Profit | (50,280) | -- | 113,517 | 1,247,235 | 980,321 | 2,138,721 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | 263,500 | 1213.625% | 20,059 | 115,699 | 315,038 | 1,061,366 | |
| Change in FV & Impairment on Others | (59,264) | -32.712% | (88,075) | (112,233) | (40,394) | (27,213) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (72,561) | -- | 42,027 | 166,385 | (5,102) | (20,351) | |
| Profit / (Loss) before Taxation | (678,620) | -37.761% | (1,090,344) | 876,867 | 516,721 | 2,046,163 | |
| Taxation | 85,117 | -10.451% | 95,051 | (532,352) | (383,076) | (826,550) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 29,532 | -64.208% | 82,511 | (116,182) | (34,905) | (359,849) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (563,971) | -38.214% | (912,782) | 228,333 | 98,740 | 859,764 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 488,055 | -25.045% | 651,128 | 287,934 | 125,053 | 274,942 |
| Depreciation & Amortisation | 95,281 | -22.553% | 123,027 | 225,239 | 95,397 | 93,571 |
| Directors' Emoluments | 6,316 | -28.088% | 8,783 | 11,644 | 14,496 | 13,962 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Disclaimer | -- | Disclaimer | Unqualified (Modified Report) | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -13.000 | -38.095% | -21.000 | 5.140 | 2.220 | 19.340 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 3.421 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | 17.690% |
| Cash flow per share ($) | 0.115 | -- | 0.136 | 0.978 | 1.111 | 1.238 |
| NBV per share ($) | 2.513 | -- | 2.640 | 2.859 | 2.811 | 2.823 |
| Remarks: | Real time quote last updated: 22/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -58,659,000 |
| %Change | -78.020% |
| EPS / (LPS) | RMB -0.013 |
| NBV Per Share (¥) | RMB 2.500 |